Navigation Links
Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
Date:10/29/2009

NEWPORT, Ky., Oct. 29 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today the completion of $50 million in equity financing. The round was led by Longitude Capital with participation from new investors Skandia and Silver Point Capital. Other current investors that participated in the financing include MPM Capital, LLC, AIG Investments' sponsored funds, Perseus-Soros Biopharmaceutical Fund, Blue Chip Venture Company, HealthCare Ventures, LLC, and Union Springs, LLC. Aquilo Partners, L.P., a life science investment bank, acted as the exclusive placement agent for the financing.

Michael J. Valentino, President and CEO commented, "I am extremely pleased to have secured additional financial resources which will be used to support our ongoing development and commercialization strategy for our emerging product portfolio."

In June 2009, Xanodyne received Food and Drug Administration (FDA) approval for Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules, a new treatment option for relief of mild to moderate acute pain in adults (18 years of age or older). Zipsor was launched nationally to physicians and patients in September.

In addition, the company expects FDA action soon on Lysteda(TM) (formerly XP12B), an oral tranexamic acid product under priority review. If approved, Lysteda would be the first and only oral therapeutic agent indicated specifically for the treatment of women suffering from cyclic heavy menstrual bleeding.

Valentino added, "The continued commitment from our investor groups allows us to remain focused on aggressively executing our product commercialization plans and optimizing the other assets in our portfolio."

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. Xanodyne markets a portfolio of products consisting of prescription pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.

SOURCE Xanodyne Pharmaceuticals, Inc.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Light Sciences Oncology Raises $40.1 Million in Series C Financing
6. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
7. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. SynergEyes, Inc. Raises $13.3 Million in Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... 2017 , ... “Childhood Memories of a Virginia Wanderer”: an entertaining look ... relive their own youth. “Childhood Memories of a Virginia Wanderer” is the creation of ... nine years. He received his BS from Idaho State University in Adult Education, ...
(Date:9/26/2017)... ... , ... “The Tour Guide”: is the life story of the author and the exciting times ... Alexander Stark, is an adventure tour guide and the subject of the book. , ... confront fifteen shocked faces. I played it off as a part of the adventure tour, ...
(Date:9/26/2017)... ... , ... “The Great Creator Saves Boobie and Ceebie”: a tool families can use to teach ... the creation of published author, G.S. White, a devoted follower of Jesus Chris who is ... , “This book is not only for children but also to glorified God in everything ...
(Date:9/25/2017)... CA (PRWEB) , ... September 26, 2017 , ... Your ... agent in February 2017 and began fulfilling a life-long wish of owner Stacy Boyle ... “I was a recipient of help when I was in high school,” said Ms. ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... and only fully programmable fall detection smart watch. VitalBand provides elite level ... contacts as you want so help arrives quickly. Plus, it’s a fully ...
Breaking Medicine News(10 mins):